Effectiveness of different vaccine schedules for heptavalent and 13-valent conjugate vaccines against pneumococcal disease in the Community of Madrid |
| |
| Institution: | 1. Epidemiology, Health Department of the Community of Madrid, Madrid, Spain;2. Health Technology Assessment Agency, Carlos III Health Institute (ISCIII-CNE), Madrid, Spain;3. Department of Public Health, University Rey Juan Carlos, Madrid, Spain;4. Regional Public Health Laboratory, Health Department of the Community of Madrid, Madrid, Spain;5. Promotion, Prevention and Health Education, Health Department of the Community of Madrid, Madrid, Spain;1. Preventive Medicine Unit, Rey Juan Carlos University, Avda de Atenas s/n, Alcorcón 28922, Madrid, Spain;2. Preventive Medicine Department, Hospital La Paz, Madrid, Spain;3. Respiratory Department, Hospital Gregorio Marañon, Madrid, Spain;1. Critical Care Department, Vall d''Hebron Hospital, Universitat Autonoma de Barcelona and Medicine Department, Vall d''Hebron Institut de Recerca (VHIR), Barcelona;2. Intensive Care Unit, Dr Negrin University Hospital, Las Palmas de Gran Canaria, Sabadell;3. Critical Care Center, Sabadell Hospital, Consorci Hospitalari Universitari Parc Taulí, Sabadell;4. Intensive Care Department, Donostia Hospital, Donostia;5. Intensive Care Department, Dr Peset University Hospital, Valencia;6. Respiratory Disease Department, Hospital Clínic i Provincial de Barcelona, University of Barcelona, Institut d''investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona;7. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Bunyola, Islas Baleares, Spain;1. Department of Respiratory Medicine, Juntendo University, Faculty of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan;2. Research Institute for Diseases of Old Ages, Juntendo University, Faculty of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan;3. Tokatsu-Clinic Hospital, 865-2 Hinokuchi, Matsudo-shi, Chiba 271-0067, Japan;4. Department of Kidney and Dialysis, Shimoochiai Clinic, 2-1-6 Shimo-Ochiai, Shinjuku-ku, Tokyo 161-0033, Japan;5. Department of Kidney and Dialysis, Tsuruta Itabashi Clinic, 7-5-7 Takinogawa, Kita-ku, Tokyo 114-0023, Japan;1. Instituto de Salud Pública de Navarra, Pamplona, Spain;2. CIBER Epidemiología y Salud Pública (CIBERESP), Spain;3. Complejo Hospitalario de Navarra, Pamplona, Spain;4. Clínica Universidad de Navarra, Pamplona, Spain;5. Hospital Reina Sofía, Tudela, Spain;6. Hospital García Orcoyen, Estella, Spain;1. Primary Care Service of Camp de Tarragona, Institut Catala de la Salut, Rambla Nova 124, D, 1°A, 43001 Tarragona, Spain;2. Department of Otorhinolaryngology, Joan XXIII Hospital, Dr. Mallafrè Guasch, 4, 43005 Tarragona, Spain;3. Department of Laboratory and Microbiology, Joan XXIII Hospital, Dr. Mallafrè Guasch, 4, 43005 Tarragona, Spain;4. Department of Laboratory and Microbiology, Santa Tecla Hospital, Rambla Vella, 14, 43003 Tarragona, Spain |
| |
| Abstract: | IntroductionThe heptavalent pneumococcal conjugate vaccine (PCV-7) was added to the childhood routine vaccination program in the Community of Madrid in November of 2006 with 3 + 1 recommended doses and a catch-up for those under 2 years old. In June 2010, PCV-7 was replaced by 13-valent vaccine (PCV-13) with 2 + 1 recommended doses. In July of 2012, the PCV-13 was removed from the funded program and reintroduced again (2 + 1 recommended doses) in December 2014. In between, children were vaccinated privately with 3 + 1 recommended doses of PCV-13. The aim of this study was to evaluate the effectiveness of each vaccination schedule used in the Community of Madrid.MethodsWe included all cases of invasive pneumococcal disease (IPD) reported between 2007 and 2015 to the Notifiable Diseases Surveillance System. Vaccination information was obtained from the Immunization Registry. Vaccine effectiveness (VE) was estimated using the indirect cohort design for cases with serotype information.ResultsA total 779 cases were included in the study. Among them 47.6% of the cases were primo-vaccinated with booster, 20% primo-vaccinated, 15.9% incompletely primo-vaccinated and 16.5% not vaccinated. The VE for ≥1 doses of any PCV was 82% (CI 95%: 67.8–89.9%): 91.9% (CI 95%: 76.5–97.2%) for PCV-7 and 77.2% (48.6–89.9%) for PCV-13. VE in those receiving the full 2 + 1 or 3 + 1 schedules was 100% for both vaccines.ConclusionsA high number of vaccine failures were reported in children before they had the opportunity to receive the booster dose, especially due to PCV-13-non-PCV-7 serotypes. VE was higher for PCV-7 compared to PCV-13, except for those that received the complete schedule with booster that achieved 100% of VE, which shows the relevance of the vaccines and complying with all doses scheduled. |
| |
| Keywords: | Pneumococcal vaccines Epidemiology Vaccination Epidemiological surveillance |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
